Unichem Laboratories Limited (UNICHEMLAB) AI Stock Analysis

• Market Cap: ₹35.40B
• Dividend Yield: N/A
• Average Volume (3M): 2.77K
• Price to Earnings (P/E): 27.1
• Beta (1Y): 0.80
• Revenue Growth: 22.04%
• EPS Growth: N/A
• Country: IN
• Employees: 2,875
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -1.49
• Shares Outstanding: 70,405,754
• 10 Day Avg. Volume: 3,475
• 30 Day Avg. Volume: 2,767
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹633.00
• Price Target Upside: 25.88% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 58 Neutral
• Price Target: ₹633.00 ▲(25.88% Upside)

Unichem Laboratories faces challenges in profitability and cash flow management, impacting its overall financial health despite strong revenue growth. Technical indicators show mixed momentum, while the stock appears moderately overvalued with no dividend support. Addressing liquidity issues and improving operational efficiencies are crucial for enhancing investor confidence.

Unichem Laboratories Limited Business Overview & Revenue Model

Company Description

Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. It offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management; and active pharmaceutical ingredients, as well as contract manufacturing services. The company was founded in 1944 and is headquartered in Mumbai, India.

How the Company Makes Money

Unichem Laboratories Limited generates revenue primarily through the sale of its pharmaceutical products. The company's revenue streams include domestic sales, international sales, and contract manufacturing. In the domestic market, Unichem sells its branded formulations through a vast distribution network to hospitals, clinics, and pharmacies. Internationally, the company exports its products to various countries, leveraging partnerships and subsidiaries to penetrate global markets. Additionally, Unichem engages in contract manufacturing, producing pharmaceutical products for other companies. The company invests in research and development to support the launch of new and innovative products, which further drives its revenue growth. Regulatory approvals and strategic partnerships also play a crucial role in expanding its market reach and enhancing its revenue potential.

Unichem Laboratories Limited Financial Statement Overview

Summary

Unichem Laboratories shows strong revenue growth and improved gross margins. However, profitability is limited with a low net profit margin, and cash flow management poses challenges with negative operating cash flow. The balance sheet is stable with low leverage, but liquidity concerns need addressing.

Income Statement

Unichem Laboratories has demonstrated significant revenue growth, with Total Revenue increasing from $11.56 billion in 2020 to $21.11 billion in 2025, a strong upward trajectory. Gross Profit Margin improved to 59.08% in 2025, highlighting enhanced efficiency. However, the Net Profit Margin remains low at 6.51% in 2025, indicating limited profitability gains. The EBIT and EBITDA margins show volatility, suggesting operational challenges despite recent improvements.

Balance Sheet

The company maintains a healthy balance sheet with Stockholders' Equity rising to $24.51 billion in 2025, demonstrating robust equity support. The Debt-to-Equity Ratio is relatively low at 0.19, indicating low leverage and financial stability. However, the Equity Ratio has slightly decreased, reflecting a minor increase in liabilities relative to assets, warranting cautious monitoring.

Cash Flow

Cash flow performance is mixed, with Operating Cash Flow turning negative in 2025, showing cash management issues. Free Cash Flow remains negative, highlighting potential liquidity challenges. The Operating Cash Flow to Net Income Ratio reflects inconsistency in cash conversion efficiency. Attention is needed to improve cash flow stability and support growth.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	20.29B	21.11B	13.43B	16.57B	12.48B	11.90B
Gross Profit	11.11B	12.47B	7.92B	3.17B	8.07B	7.89B
EBITDA	3.02B	2.65B	-466.67M	742.36M	1.18B	1.41B
Net Income	1.51B	1.38B	-2.02B	-704.74M	330.62M	343.25M
Balance Sheet
Total Assets	35.69B	35.69B	31.93B	31.69B	33.19B	31.26B
Cash, Cash Equivalents and Short-Term Investments	1.18B	1.18B	1.89B	1.52B	3.73B	3.14B
Total Debt	4.60B	4.60B	3.14B	2.48B	3.49B	1.19B
Total Liabilities	11.19B	11.19B	7.58B	8.07B	7.00B	5.69B
Stockholders Equity	24.51B	24.51B	24.35B	23.62B	26.18B	25.57B
Cash Flow
Free Cash Flow	0.00	-1.44B	-1.29B	-58.53M	-3.87B	-2.55B
Operating Cash Flow	0.00	-70.20M	-850.91M	166.94M	-2.60B	330.99M
Investing Cash Flow	0.00	-2.41B	2.03B	504.04M	1.00B	-735.58M
Financing Cash Flow	0.00	1.84B	-813.00M	-1.06B	1.91B	-1.21B

Unichem Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 502.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:UNICHEMLAB, the sentiment is Negative. The current price of 502.85 is below the 20-day moving average (MA) of 504.59, below the 50-day MA of 546.81, and below the 200-day MA of 632.52, indicating a bearish trend. The MACD of -9.34 indicates Negative momentum. The RSI at 41.91 is Neutral, neither overbought nor oversold. The STOCH value of 71.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:UNICHEMLAB.

Unichem Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AARTIDRUGS	65 Neutral	47.91B	25.38	12.28%	0.19%	-0.03%	21.33%
GUFICBIO	59 Neutral	37.05B	59.89	11.59%	0.03%	2.37%	-30.78%
UNICHEMLAB	58 Neutral	₹35.40B	27.06		―	22.04%	―
DCAL	58 Neutral	47.06B	45.15	0.06%	―	19.85%	0.00%
SEQUENT	54 Neutral	50.52B	169.00	3.11%	―	12.33%	439.46%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Unichem Laboratories Limited Corporate Events

Unichem Laboratories Updates RTA Contact Details

Unichem Laboratories Limited announced a change in the contact details of its Registrar and Share Transfer Agent, now known as MUFG Intime India Private Limited. This update follows a previous name change from Link Intime India Private Limited. The company has provided new contact information and emphasized that electronic queries or service requests should be made through the RTA’s website. This change is part of the company’s ongoing efforts to streamline operations and improve stakeholder communication.